HISTAMINE IS A NEUROTRANSMITTER
The first indication of the functional importance of histamine in the CNS can be traced back to the 1930's, when it was observed that centrally penetrating histamine H 1 antagonists had marked sedative properties. Yet, no attention was given to histamine receptors as sites of action for these unwanted effects (1) . Indeed, histamine role as aneurotransmitter has been neglected for many years, in spite of early reports of its presence in the brain (2) , and suggestions that this amine has central functions (3) . The delay in searching for a histaminergic neuronal system, compared to the exploration of other aminergic neurotransmitter systems, may rest on the methods available for their visualization. The distribution of the catecholaminergic and serotonergic neurons in the brain became known using a fluorescent immunohistochemical analysis with o-phtalaldehyde as a tracer (4) . However, the same method was not suitable for visualizing histamine because of a strong interference with the ubiquitous spermidine (5) . The first direct evidence of the existence of histaminergic neurons came only in the 1980's, with the development of immunohistochemistry using antibodies against histamine (6) and histidine decarboxylase (7) . All histaminergic neurons are localized in the tuberomammillary nucleus (TMN) of the posterior hypothalamus (6, 7) , that is also location of histidine decarboxylase immunoreactivity (8) , an essential determinant of brain histamine levels (9, 10) . They project to almost all regions of the central nervous system (11) mostly unmyelinated fibers that, with the exception of the mesencephalic trigeminal nucleus (12) , do not form synaptic contacts, but present diffuse varicosities containing synaptic vesicles (13, 14) . This peculiarity suggests that histamine may act as a local hormone affecting not only neuronal, but also glial activity and blood vessel tone (15) . Consistently, cultured astrocytes from rat cerebral cortex display histamine receptors identical to those present on neuronal cells (16, 17 (26) , where it acts as a presynaptic autoreceptor that restricts histamine release as well as synthesis both in vitro (20), and in vivo (27) (28) (29) (30) . The H 3 R is located also on histaminergic somata where it provides a tonic inhibition of firing (31) .
Moreover, the presence of the H 3 R is not restricted to histaminergic neurons (32) (33) (34) . Accordingly, H 3 Rs act also as heteroreceptors modulating the release of other neurotransmitters, including ACh (35, 36) , dopamine (37), noradrenaline (38) and serotonin (39, 40) from brain regions crucial for the maintenance of alertness or the storage of information (1) . Network analyses of the brain and its dysfunction suggest that agents with multiple and complementary modes of action are more likely to show broad-based efficacy against core and comorbid symptoms. Thus, the regulatory role in the release of histamine and other neurotransmitters makes the H 3 R an attractive target for therapies of CNS disorders, and H 3 R ligands are good therapeutic candidates for their simultaneous exploitation of multiple neuronal systems.
Consistently with the widespread distribution throughout the entire central nervous system of histaminergic fibers (41, 42) , brain histamine is, directly or indirectly, involved in a variety of basic homeostatic and higher brain functions, such as sleep-wake cycle, appetite, nociception, cognition and emotion (1, 5) . H 3 R antagonists/inverse agonists have been shown to increase wakefulness, improve cognitive performances and reduce body weight in animal models (5) . Such findings hint at the potential use of these compounds for the treatment of Alzheimer's Disease and other dementias, ADHD, cognitive deficits in schizophrenia, obesity and sleep disorders (43) (44) (45) (46) . Thus, it is not surprising that much effort is focused on the development of clinically suitable H 3 R antagonists/inverse agonists by academic and industrial laboratories (45) (46) (47) . As a result, more and more H 3 R 
CHARACTERISTICS OF THE H 3 R
H 3 R is largely confined to the nervous system and the highest levels were found in the cerebral cortex, hippocampus, basal ganglia, and hypothalamus (33, 34) . This receptor has multiple splice variants. Not all isoforms appear to be functional and some of them might regulate functional isoforms by associating with them (48 in cognitively impaired animals: as observed in senescence-accelerated mice or scopolamine-impaired rats challenged in a passive-avoidance response (63, 64) , scopolamine-impaired rats tested in the object recognition (43, 64, 65) or the elevated plus-maze paradigm (66) , and MK-801-treated rats evaluated in the radial maze (67) . Administration of non-imidazole H 3 R antagonists/inverse agonists, A-304121 or A-317920 improved cognitive performances also in spontaneously hypertensive rat pups, which were normotensive during early development, but exhibited many cognitive impairments (60, 61) . Certainly, such a model is clinically very relevant, as deficits are genetic in origin and do not require pharmacological or surgical intervention. Although another report provided some contrasting data, as
H 3 R antagonists/inverse agonists impaired object recognition in wild-type and
Apoe -/mice (68), these findings may be relevant to predict the potential of H 3 R antagonists/inverse agonists in ameliorating cognitive dysfunctions in humans (61) . In this regard, it is important the demonstration that
[3H]GSK189254 labeled H 3 Rs in hippocampal and cortical sections from patients with advanced AD (69), suggesting the persistence of H3Rs even in severe AD.
If cognitive deficits are related to reduced availability of acetylcholine (ACh) in the synaptic cleft (70), increase of ACh release in the prefrontal cortex exerted by H 3 R antagonists/inverse agonists could account for the procognitive effects produced by these compounds, at least in short term memory paradigms with important cortical cholinergic components, such as object recognition (71) proposed to alleviate disorders such as post-traumatic stress syndrome (PTSD), panic attacks, specific phobias and generalized anxiety.
Brain histamine affect emotional memory also eliciting ERK2 phosphorylation in hippocampal CA3 pyramidal cells, an event that is crucial for the consolidation of contextual fear memory (88) .
AROUSAL ELICITED BY H 3 R ANTAGONISTS/INVERSE AGONISTS AND

ITS CONTRIBUTION TO PROCOGNITIVE EFFECTS
Cognition is a complex phenomenon involving the integration of multiple neurological activities among which arousal is crucial (89, 90) . Histamine is, along with orexin, one of the major wake-promoting neurotransmitters in the central nervous system (91) , as histidine decarboxylase knock-out mice that lack histamine, are unable to remain awake when high vigilance is required (92) . Also narcoleptic dogs show histamine deficiency (93) . It is known that histaminergic neurons fire at higher frequency during wakefulness than during sleep (94) . Moreover, histamine is responsible for cortical EEG desynchronization (91), a salient sign of wakefulness (1, 95) . Brain histamine elicits cortical activation directly, through excitatory interactions with cholinergic corticopetal neurons originating from the substantia innominata (96) and the nucleus basalis magnocellularis (75) , and indirectly, as it activates, through stimulation of cholinergic neurons in the mesopontine tegmentum, thalamo-and hypothalamo-cortical circuitries (97) . H 3 R blockade by local perfusion of thioperamide into the TMN increased the time spent in wakefulness along with the release of TMN histamine in freely moving rats (76) , thus suggesting that they, by increasing arousal, may enhance attention and improve cognitive performances. However, several H 3 R antagonists/inverse agonists produced cognitive enhancing effects at much lower doses than those required to elicit a robust wake enhancement (59, 61) . For example, ABT-239 produced no detectable change in slow-wave EEG at 30 mg/kg, whereas it was effective in social recognition at 0.01 mg/kg (59) . Consistently, for ciproxifan, thioperamide or GSK189254, only a relatively low level of cumulative wake activity was linearly correlated with up to 80% of the receptor occupancy, and an abrupt break from linearity along with a robust increase of waking activity was observed at doses that produced greater than 80% occupancy (98 instance, ischemic neuronal damage or neurodegenerative diseases. As a matter of fact, schizophrenic patients have impaired Akt/GSK-3β signalling (108) and evidence points to a key role for GSK-3β in promoting neurodegeneration (109) . GSK3 is involved in a cascade of events, such as hyperphosphorylation of tau protein, increased production of β-amyloid, local cerebral inflammatory responses that may culminate in Alzheimer's disease (110) . In this regard, binding studies showed that the expression of H 3 R is spared in the brain of Alzheimer's patients (78) . To fully understand the impact of H 3 R-induced activation of antiapoptotic pathways in the CNS,
in vivo experiments are necessary, the more so as H 3 R antagonists are now viewed as potential therapeutics for schizophrenia (77) and Azheimer's disease (78) .
HETEROGENEITY OF HISTAMINERGIC NEURONS
In a comparable architecture to noradrenergic, dopaminergic, and serotonergic systems (111, 112) , somata of histaminergic neurons are restricted to discrete cell clusters in the hypothalamic TMN, and send their axons to innervate nearly the entire central nervous system (6, 7) .
Cathecolaminergic and serotonergic nuclei are comprised of distinct compartments with respect to projection fields, as distinct sets of axons innervating separate brain regions originate from separate subgroups of noradrenergic (A1-A7), dopaminergic (A8-A17), and serotonergic (B1-B9) neurons (111, 112) . This does not seem to be the case for the histaminergic system, as retrograde tracers injected into different CNS regions labeled histaminergic somata scattered throughout the TMN without a strict topographical pattern (8, 11, 113) . Noradrenergic, dopaminergic, and serotonergic patterns imply independent functions of sets of neurons according to their origin and terminal projections. On the contrary, the morphological feature of the histaminergic system is consistent with the hypothesis of a single regulatory network for whole-brain activity, which modulates general states of metabolism and consciousness, rather than processing specific functions (15) . However, very recently direct evidence demonstrated that histaminergic neurons as well are organized into functionally distinct circuits impinging on different brain regions, and displaying selective control mechanisms. Using the double-probe microdialysis technique in freely-moving rats it was observed that histaminergic neurons established distinct pathways related to independent functions according to their terminal projections, and to their sensitivity to H 3 R antagonists/inverse agonists or GABA A -receptor antagonists (65, 76) . GABA A -R activation inhibits directly histaminergic cell firing rate (114, 115) , whereas inhibition increases significantly TMN histamine release (116) . Depending on GABA A -R subunit expressions, histaminergic neurons displayed different sensitivity to GABA (117, 118) . This may account for the functional heterogeneity of GABAergic responses displayed by histaminergic neurons following stimulation of the diagonal band of Broca, the antero-lateral hypothalamus, or the lateral preoptic area (114) . The finding that Intra-hypothalamic perfusion of bicuculline increased histamine release from the TMN, the nucleus accumbens and cortex, but not from the striatum (76) , indicates that sensitivity to bicuculline relates to TMN neurons heterogeneity also with respect to projection fields. (65, 76) , thus suggesting that histamine neurons are more functionally heterogeneous than previously thought (15) . 
